KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Cash from Financing Activities: 2018-2024

Historic Cash from Financing Activities for Royalty Pharma (RPRX) over the last 7 years, with Dec 2024 value amounting to $361.1 million.

  • Royalty Pharma's Cash from Financing Activities rose 272.88% to $562.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.1 billion, marking a year-over-year decrease of 395.53%. This contributed to the annual value of $361.1 million for FY2024, which is 116.81% up from last year.
  • According to the latest figures from FY2024, Royalty Pharma's Cash from Financing Activities is $361.1 million, which was up 116.81% from -$2.1 billion recorded in FY2023.
  • In the past 5 years, Royalty Pharma's Cash from Financing Activities ranged from a high of $1.5 billion in FY2020 and a low of -$2.1 billion during FY2023.
  • Its 3-year average for Cash from Financing Activities is -$910.8 million, with a median of -$944.9 million in 2022.
  • In the last 5 years, Royalty Pharma's Cash from Financing Activities soared by 224.80% in 2020 and then tumbled by 345.35% in 2022.
  • Over the past 5 years, Royalty Pharma's Cash from Financing Activities (Yearly) stood at $1.5 billion in 2020, then crashed by 74.10% to $385.1 million in 2021, then tumbled by 345.35% to -$944.9 million in 2022, then plummeted by 127.42% to -$2.1 billion in 2023, then soared by 116.81% to $361.1 million in 2024.